Inhibrx Biosciences (INBX) Stock Price, News & Analysis

Company Overview

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Key Stats

• Today's Range: $24.00 to $25.61
• 50-Day Range: $14.27 to $25.00
• 52-Week Range: $10.81 to $25.61
• Volume: 223,561 shs
• Average Volume: 105,720 shs
• Market Capitalization: $362.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Inhibrx Biosciences Stock Analysis - MarketRank™

Inhibrx Biosciences scored higher than 33% of companies evaluated by MarketBeat, and ranked 709th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Inhibrx Biosciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Inhibrx Biosciences are expected to decrease in the coming year, from $104.88 to ($12.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Inhibrx Biosciences is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inhibrx Biosciences is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inhibrx Biosciences has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.86% of the float of Inhibrx Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Inhibrx Biosciences has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Inhibrx Biosciences has recently decreased by 24.67%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inhibrx Biosciences does not currently pay a dividend.

Dividend Growth

Inhibrx Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -1.21

Percentage of Shares Shorted

6.86% of the float of Inhibrx Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Inhibrx Biosciences has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Inhibrx Biosciences has recently decreased by 24.67%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.59

News Sentiment

Inhibrx Biosciences has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Inhibrx Biosciences this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for INBX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inhibrx Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.09% of the stock of Inhibrx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

82.46% of the stock of Inhibrx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INBX Stock Analysis - Frequently Asked Questions

How have INBX shares performed this year?

Inhibrx Biosciences' stock was trading at $15.40 at the beginning of 2025. Since then, INBX stock has increased by 62.3% and is now trading at $25.00.

How were Inhibrx Biosciences' earnings last quarter?

Inhibrx Biosciences, Inc. (NASDAQ:INBX) announced its earnings results on Wednesday, August, 13th. The company reported ($1.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.92) by $1.07. The firm had revenue of $1.30 million for the quarter.

When did Inhibrx Biosciences IPO?

Inhibrx Biosciences (INBX) raised $102 million in an IPO on Wednesday, August 19th 2020. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are Inhibrx Biosciences' major shareholders?

Inhibrx Biosciences' top institutional shareholders include Perceptive Advisors LLC (6.75%), Sofinnova Investments Inc. (4.89%), Geode Capital Management LLC (1.56%) and Kennedy Capital Management LLC (1.22%). Insiders that own company stock include Brendan P Eckelman, Mark Lappe, Global Investors Lp Viking, Jon Faiz Kayyem and Kristiina Md Vuori.
View institutional ownership trends.

How do I buy shares of Inhibrx Biosciences?

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inhibrx Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibrx Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Shopify (SHOP), Zoom Communications (ZM), CrowdStrike (CRWD) and Moderna (MRNA).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 8/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INBX
• CIK: 1739614
• Web: www.inhibrx.com
• Phone: 858-795-4220
• Fax: N/A
• Employees: 166
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($10.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 0.24
• P/E Growth: N/A
• Net Income: $1.69 billion
• Net Margins: N/A
• Pretax Margin: -11,692.29%
• Return on Equity: -137.83%
• Return on Assets: -76.31%

Debt

• Debt-to-Equity Ratio: 1.45
• Current Ratio: 4.98
• Quick Ratio: 4.98

Sales & Book Value

• Annual Sales: $1.40 million
• Price / Sales: 258.66
• Cash Flow: $119.05 per share
• Price / Cash Flow: 0.21
• Book Value: $4.73 per share
• Price / Book: 5.29

Miscellaneous

• Outstanding Shares: 14,485,000
• Free Float: 12,010,000
• Market Cap: $362.13 million
• Optionable: Optionable
• Beta: 0.24